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Abstract
Background: Angiogenesis may play a role in the pathogenesis of Non-Small Cell Lung cancer (NSCLC). The CXC (ELR
+)
chemokine family are powerful promoters of the angiogenic response.
Methods: The expression of the CXC (ELR
+) family members (CXCL1-3/GROa-c, CXCL8/IL-8, CXCR1/2) was examined in a series
of resected fresh frozen NSCLC tumours. Additionally, the expression and epigenetic regulation of these chemokines was
examined in normal bronchial epithelial and NSCLC cell lines.
Results: Overall, expression of the chemokine ligands (CXCL1, 2, 8) and their receptors (CXCR1/2) were down regulated in
tumour samples compared with normal, with the exception of CXCL3. CXCL8 and CXCR1/2 were found to be epigenetically
regulated by histone post-translational modifications. Recombinant CXCL8 did not stimulate cell growth in either a normal
bronchial epithelial or a squamous carcinoma cell line (SKMES-1). However, an increase was observed at 72 hours post
treatment in an adenocarcinoma cell line.
Conclusions: CXC (ELR
+) chemokines are dysregulated in NSCLC. The balance of these chemokines may be critical in the
tumour microenvironment and requires further elucidation. It remains to be seen if epigenetic targeting of these pathways
is a viable therapeutic option in lung cancer treatment.
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Introduction
Angiogenesis is important in the growth and spread of cancer
and also influences inflammatory changes which may pre-dispose
to the disease [1]. The CXC (ELR
+) chemokines induce
angiogenesis and may be important in cancers that have an
angiogenic phenotype such as NSCLC [2].
The term chemokine refers to a family of low molecular weight
(8–10 kDa) chemotactic cytokines. Chemokines are small inducible
cytokines, which are chemo-attractants for leukocytes. Chemokines
are classified by their amino acid composition, functional activity
and receptor binding properties and comprise of four sub families
defined according to the first two of four conserved cysteine residues
(a) C, (b) CC, (c) CXC and (d) CXXXC [3]. The CXC chemokine
family consists of two subtypes, ELR
+ and ELR
2, according to a
particular Glu-Leu-Arg (ELR) motif preceding the first cysteine
residue [3]. CXC (ELR
+) promoters contain a putative cis element
that recognises NF-kB, and therefore can cause the trans-activation
of CXC chemokines [4].
The angiogenic receptor for CXCL8 and the other CXC
(ELR
+) chemokines is CXCR2 [5]. Blockade of this receptor leads
to a decrease in angiogenesis in pancreatic cancer [6], and a
significant inhibition of human melanoma tumour growth and
experimental lung metastases in CXCR22/2 mice, as well as a
reduction in angiogenesis [7]. Within the setting of the lung,
cancer growth and metastatic potential is down-regulated in
several mouse CXCR22/2 models [7,8]. However, CXCL8 can
bind to CXCR1 and CXCL1/CXCL8 can also bind DARC,
although binding to DARC does not transduce a signal. Currently,
studies with DARC suggest that it acts by ‘mopping’ up
chemokines and, therefore, reducing their signalling capacity.
Over-expression of DARC leads to increased tumour growth,
however, this was due to the induction of large necrotic areas
within the tumour [9,10].
Chemokine receptors are up-regulated on tumour cells,
allowing the tumour to take advantage of chemokine rich
environments, promoting tumour growth and vasculature. In
addition, chemokines can recruit macrophages, which detect the
hypoxic environment within the tumour and subsequently secrete
pro-angiogenic factors [11,12]. Initially chemokines were thought
to only play a role in attracting specific leucocytes to a site of
injury; nevertheless it has now been shown that they are involved
in the neoplastic transformation of a cell, promotion of
angiogenesis, tumour clonal expansion and changes in the ECM,
and in particular mediate organ specific metastases in cancer [13].
Specific ligand receptor pairs dictate the metastases patterns of
breast and lung cancer [14]. In breast cancer metastases to the
lung, CXCL1 was part of a gene signature that also included
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derived CXCL8 acted as an attractant for circulating tumour cells
to return to the original tumour, leading to a more aggressive
tumour phenotype [16].
A variety of CXC chemokines have been detected in neoplastic
tissues as products of tumour cells or stromal elements [12]. For
example, tumour infiltrating inflammatory cells elevates CXCL8
levels in bronchioalveolar cells, along with its two receptors [17].
Strong evidence suggests that CXC (ELR
+) chemokines have a
role in cancer promotion, as they can promote growth and survival
of cancer cells [18].
The growth and progression of cancer is dependant on
angiogenesis and CXCL8 has been demonstrated to play a role
in its angiogenic and tumourigenic potential. In renal cell cancer
the levels of CXCL1, CXCL3 and CXCL8 were elevated
compared to controls and in receptor negative (CXCR22/2)
mice there was a corresponding reduction in tumour growth [19].
Studies using melanoma tumour models support the role of
CXCL1, CXCL2, and CXCL3 in mediating tumour angiogenesis
and levels of all three chemokines are highly expressed in
melanoma tumours. Transfection of CXCL1–3 into immortalised
non-tumorigenic cells gave them the ability to form tumours
[20,21]. CXCL8 is one of the most studied members of the CXC
(ELR
+) family, particularly in lung cancer. CXCL8 was identified
in a gene expression signature that was predicative of poor
prognosis in patients with stage I lung cancer [22], while levels of
CXCL8 are significantly increased in both malignant pleural
effusions [23] and NSCLC [24], where levels increase with stage
[25] and correlate with patient survival/relapse [26].
Chemokines found within the tumour microenvironment are
thought to play at least five roles in the development of tumours
and metastatic disease; (a) control leukocyte infiltrate, (b) modify
tumour immune response, (c) regulate angiogenesis, (d) operate as
growth and survival factors, and (e) direct the movement of
tumour cells themselves [27]. The CXC (ELR
+) ligands and
receptors are particularly important in mediating NSCLC tumour
associated angiogenesis [28] and organ specific metastases [13,14].
CXCR2 ligands have also been implicated in NSCLC tumour
progression through Snail, high levels of which correlate with
decreased survival [29].
Aberrant epigenetic regulation of gene expression is a frequent
event in NSCLC [30,31]. Targeting these epigenetic regulatory
mechanisms in NSCLC is an active area of pharmaceutical
research. We sought to examine the expression of the CXC
(ELR
+) chemokines and their receptors in a series of primary
NSCLC tumour samples and in an additional panel of NSCLC
cell lines, and to directly examine whether epigenetics plays a role
in the regulation of these genes in this disease. Our results indicate
that the expression of these chemokines and their receptors are
frequently deregulated in NSCLC, being regulated via directly and
in directly by epigenetic mechanisms (histone post-translational
modifications and DNA CpG methylation, respectively) and may
be good candidate targets for epigenetic therapy in the treatment
of this cancer.
Methods
Cell lines
The A549 (adenocarcinoma), SKMES-1 (squamous cell carci-
noma), H460, H647 and H1299 (large cell carcinoma) and BEAS-
2B (transformed normal bronchoepithelial) cell lines were pur-
chased from the ATCC (LGC Promochem, Teddington, UK).
HBEC cell lines [32] were a gift from Prof. John D Minna (Hamon
Centre for Therapeutic Oncology Research, UTSoutwestern,
Dallas, TX, USA). All cell culture reagents were purchased from
Lonza(Walkersville,MD,USA). Cellsweremaintained at37uCi na
humidified atmosphere containing 5% CO2 in the following media;
A549 - F-12 (Ham) medium supplemented with 10% (v/v) FBS,
penicillin streptomycin (500 U/mL) and 2 mM L-glutamine.
BEAS-2B were also maintained in F-12 (Ham) medium without
the addition of FBS. SKMES-1 - EMEM with the addition of 10%
(v/v) FBS, penicillin streptomycin (500 U/mL), 2 mM L-glutamine
and 0.1 M non-essential amino acids. All large cell carcinoma lines
were maintained in RPMI with 10% FBS and penicillin
streptomycin (500 U/mL). HBEC lines were maintained in
Keratinocyte serum-free media (SFM), with L-glutamine (GIBCO
Invitrogen,Paisley,Scotland) andsupplemented with 2.5 mg human
recombinant epidermal growth factor (rEGF), and 25 mg bovine
pituitary extract (GIBCO Invitrogen).
Primary tumour samples
A series of 37 tumour specimens (14 adenocarcinoma and 23
squamous cell carcinoma) were taken from patients presenting
with early stage NSCLC at St. James’s Hospital, Dublin. Matched
normal tissue was taken in parallel for each patient and samples
were evaluated by a pathologist immediately following dissection.
Reagents
Trichostatin A (TSA) was purchased from Calbiochem (San
Diego, CA, USA) and dissolved in DMSO to a concentration of
250 mg/mL. Cell cultures were treated for a period of 16 h, at a
final concentration of 250 ng/mL.
Phenylbutyrate (PB) (Tributyrate
TM) was a gift from Triple
Crown America, Perkasie, PA, USA. Cell cultures were treated at
a final concentration of 10 mM for 16 h.
5-Aza-29-Deoxycytidine (DAC) was purchased from Merck
(Darmstadt, Germany) and dissolved in methanol. Cell cultures
were treated with DAC (final concentration - 1 mM) for 48 h with
DAC and media replaced every 24 h.
Recombinant human CXCL8 was purchased from PromoKine
(PromoCell GmbH, Heidelberg, Germany) and reconstituted in
sterile distilled water.
SB 225002 was purchased from Cayman Chemical (Ann Arbor,
MI, USA) and dissolved in DMSO to a concentration of 2.2 mM.
Cell lines were treated for one hour prior to the addition of
CXCL8, at a concentration of 0.022 mM.
Total RNA isolation and RT-PCR amplification
Total RNA was extracted using TRI reagentH (Molecular
Research Center, Montgomery Road, OH, USA) according to
manufacturer’s instructions. Prior to first strand cDNA synthesis,
10 mg of total RNA was pre-treated by digestion with RQ1 DNase
(Promega, Madison, WI, USA) according to the manufacturer’s
instructions. cDNA was generated using Superscript III (Invitro-
gen Corp., Carlsbad, CA, USA) and Oligo dT(20) primers
(Eurofins MWG Operon, Ebersberg, Germany) according to the
manufacturer’s instructions.
Cell lines were examined for the expression of CXCL1–3,
CXCL8, CXCR1/2 and Beta-actin by RT-PCR, using primers and
annealing temperatures outlined in Table 1. PCR cycling
conditions consisted of 295uC for 5 min followed by 35 cycles
of 1 min at 94uC, 1 min at the target gene annealing temperature
and 1 min at 72uC with a final extension at 72uC for 10 min.
Experiments were carried out in triplicate and products
electrophoresed on a 1% agarose gel. Product quantification was
performed using TINA 2.09c (Raytest, Isotopenmeßgera ¨te
GmbH, Straubenhardt, Germany) densitometry software. The
mRNA expression was normalised to Beta-actin controls, and was
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Chromatin immunoprecipitation (X-ChIP)
Chromatin immunoprecipitation was performed as follows:
Following treatments, cells were fixed with formaldehyde (final
concentration 1%), suspended in SDS lysis buffer (Millipore,
Billerica, MA, USA) and sonicated until DNA was fragmented
into lengths of between 200–1000 bp. Aliquots of this sheared
DNA were subsequently immunoprecipitated using the OneDay
ChIP Kit
TM (Diagenode, Liege, Belgium) according to the
manufacturer’s instructions. The antibodies used for immunopre-
cipitation were as follows: pan acetyl-histone H3 (Millipore
Cat#06-599), pan acetyl histone H4 (Millipore Cat# 06-598),
acetyl-histone H3 (K9/14ac) (Diagenode Cat# pAb-ACHBHS-
044), acetyl-histone H3 (K9ac) (Diagenode Cat# pAb-ACHAHS-
044), acetyl phospho - histone H3 (K9pS10) (Sigma Cat# H0788),
di methyl-histone H3 (K9Me2)(Sigma Cat# D5567), di methyl
histone H3 (K4Me2) (Sigma Cat# D5692) and methyl-histone
H3(K4Me) (Sigma Cat# M4819). A no antibody control was
included to test for non specific binding.
Primers used to study the promoter regions of CXCL8 and
CXCR1/2 by ChIP were designed from the known 59 UTRs
contained within their nucleotide sequences. RT-PCR cycling
conditions were the same as those outlined above. Primers and
annealing temperatures for ChIP are presented in Table 2.
ELISA
The concentration of CXCL8 was measured in conditioned
media using a DuoSetH ELISA Development Systems (R & D
systems, Minneapolis, MN, USA) in line with manufacturer’s
instructions, with one exception; the substrate solution used was
made in phosphate citrate buffer (containing citric acid and
Disodium hydrogen orthophosphate dodecahydrate, pH 5.0),
10 mg of 1, 2-phenylenediamine dihydrochloride (OPD) and
18 mLo f1MH 2O2.
CXCL2 was quantified using an ELISA development kit
purchased from Strathmann Biotec (Hamburg, Germany),
according to manufacturer’s instructions.
Cellular proliferation assays
Cell proliferation was measured using a Cell Proliferation
ELISA, BrdU (Roche Diagnostics Ltd., Sussex, UK). Briefly, cells
were seeded at 5610
3/well in a 96-well plate and adhered
overnight. Subsequently the complete media was removed and the
cells washed with 100 mL PBS. Serum depleted media (0.5% FBS)
was added to the lung cancer cells only, as this mimics more
closely physiological conditions. Following overnight incubation,
cells were treated for 24, 48 or 72 h with human recombinant
CXCL8 at various concentrations (0.1–100 ng/mL). Inhibition
studies were carried out by pre-treating cells with 0.022 mM
SB225002 for 1 h prior to the addition of CXCL8. Absorbance
was measured on a plate reader at 450 nm with a reference
wavelength set to 690 nm and blank and untreated wells were
used for normalisation purposes. The untreated cells were set as
100%, and the CXCL8 treatments assessed relative to this.
Statistical analysis
The data are expressed as mean 6 SEM (standard error of the
mean). Statistical analysis was performed with InStat (Graphpad
software, La Jolla, CA, USA) using a paired one tailed Student’s
t-test. Differences were considered significant when p,0.05.
Results
Expression of CXCL1–3, CXCL8 and CXCR1/2 in primary
lung cancer tumour specimens
To assess the expression of a number of CXC (ELR
+) family
members in a panel of normal/tumour matched patient samples
from Stage I and II patients, RT-PCR was performed (Figure 1A),
and summarized in Figure 1B. Densitometric analysis of the RT-
PCR revealed a significant decrease in the expression of CXCL1,
CXCL2 (p,0.01) and the CXCR1 receptor (p,0.05) in NSCLC
tumour samples compared with normal (Figure 1C).
Expression of CXCL1–3, CXCL8 and CXCR1/2 in a panel of
normal and lung cancer cell lines
Utilizing RT-PCR, the chemokines were examined in a panel of
normal and NSCLC cell lines (Figure 2). All cell lines tested
expressed varying levels of CXCL1–3 and CXCL8, with higher
basal expression observed in the NSCLC lines. However, robust
expression of both receptors (CXCR1/2) was detected in the
normal cell lines (HBEC3–5).
Histone acetylation is involved in the regulation of CXCL8
and CXCR1/2 expression
Using the histone deacetylase inhibitor (HDACi), Trichostatin
A (TSA), an induction of CXCL8 and CXCR1/2 in both the
Table 1. Primers and annealing temperatures for RT-PCRs.
Primer Set Sequence
Annealing
Temp (6C)
CXCL1 (324 bp) F: 59-ATGGCCCGCGCTGCTCTCTC-39 55
R: 59-TCAGTTGGATTTGTCACTGTTC-39
CXCL2 (324 bp) F: 59-ATGGCCCGCGCCACGCTCTC-39 55
R: 59-TCAGTTGGATTTGCCATTTTTCAGC-39
CXCL3 (324 bp) F: 59-ATGGCCCACGCCACGCTCTCCG-39 60
R: 59-TCAGTTGGTGCTCCCCTTGTTC-39
CXCL8 (297 bp) F: 59-ATGACTTCCAAGCTGGCCGTG-39 55
R: 59-TGAATTCTCAAGCCCTCTTCA-39
CXCR1 (512 bp) F: 59-CCTTCTTCCTTTTCCGCCAG-39 60
R: 59-AAGTGTAGGAGGTAACACGATG-39
CXCR2 (300 bp) F: 59-CTGCTCTGCTGGCTGCCCTA-39 60
R: 59-GAGAGTAGTGGAATTGTGCCC-39
Beta-actin (510 bp) F: 59-TGTTTGAGACCTTCAACACCC-30 55
R: 59-AGCACTGTGTTGGCGTACAG-39
doi:10.1371/journal.pone.0014593.t001
Table 2. Primers and annealing temperatures for X-ChIP.
Primer Set Sequence
Annealing
Temp (6C)
CXCL8 (171 bp) F: 59-AAGAAAACTTTCGTCATACTCCG-39 55
R:59-TGGCTTTTTATATCATCACCCTAC-39
CXCR1 (120 bp) F: 59-TCAACCCCAGCTTCACACCT-39 56
R: 59-CCCCACCCATGTCTACATTT-39
CXCR2 (215 bp) F: 59-CCACTGGATCCCTTGCAGAC-39 60
R: 59-GGAAACTTCCCACCAGTGAA-39
doi:10.1371/journal.pone.0014593.t002
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+) chemokine family mRNA expression in normal/tumour NSCLC matched pairs. A) Levels of CXCL1–3, CXCL8 and
CXCR1/2 were examined by RT-PCR on a panel of NSCLC lines (adenocarcinoma (n=14), squamous cell carcinoma (n=23)) patient samples.
Representative images of up and down regulated samples are shown. Beta actin levels were used for normalisation purposes. B) A summary of the
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with a concomitant decrease in CXCL1–3 (SKMES-1, p,0.05)
(Figure 3A) was observed. The induction of CXCL8 was significant
in HBEC4 and SKMES-1 (p,0.05), as was the increase in CXCR1
and CXCR2 in both the lung cancer cell lines (A549 - p,0.05,
SKMES-1 – p,0.01) and CXCR1 in HBEC4 (p,0.05) (Figure 3B).
The reactivation of the expression of these receptors in the
NSCLC cell lines would indicate that these genes are epigenet-
ically regulated at the level of histone acetylation. Treatment of
cell lines with an additional histone deacetylase inhibitor,
phenylbutyrate (PB), also resulted in a reactivation of CXCR1/2
(data not shown), indicating that the results are HDACi specific.
Two chemokines were selected, CXCL2 and CXCL8, for the
determination of protein expression by ELISA. The pattern
observed reflected that seen at the mRNA level in SKMES-1, with
a decrease in CXCL2 and an increase in CXCL8 with TSA
treatment (p,0.05) (Figure 3C). However, there was no significant
change in protein levels in either A549 or HBEC4 between basal
and TSA treated cells (data not shown).
Regulation of CXCL8 and CXCR1/2 occurs through direct
chromatin remodelling
To confirm that the observed effects for HDACi were due to
increased histone hyperacetylation at the promoters of the CXCL8
and CXCR1/2 genes, we carried out chromatin immunoprecip-
itation (ChIP) analysis of the individual promoters from A549 cells
treated with TSA. As can be seen in Figure 4, treatment with TSA
results in an increase in the amount of PCR product for CXCL8
and CXCR1/2 indicating enhanced histone hyperacetylation
around the promoters for these genes. We show that lysine 9
and lysine 14 are hyperacetylated in this region following
treatment with TSA. This experiment clearly demonstrates that
chromatin remodelling is directly involved with the activation of
CXCL8 (Figure 4A), CXCR1 (Figure 4B) and CXCR2 (Figure 4C)
gene expression. In addition, we also observed an increase in
histone H3 lysine 4 tri-methylation (H3K4me3) at the CXCR1
promoter (data not shown) and the phosphorylation of Serine 10
(H3K9pS10) at the CXCL8 promoter. An increase in H3K4
diemethylation (H3K4Me2) was detected with a simultaneous
decrease in H3K9 dimethylation (H3K9Me2) at the promoter
region. These modifications have been associated with the
activation of transcription and early response genes, respectively,
and add additional strength to the evidence that these genes are
dynamically regulated by histone pos-translational modifications.
Methylation is not directly involved in the regulation of
the CXC (ELR
+) family
Following treatment of cells with a DNA methyltransferase
inhibitor (DAC), the effects on CXC (ELR+) family expression
were examined using RT-PCR (Figure 5). A significant reduction
of CXCL3 (p,0.01) was observed in the HBEC4 cell line and not
in any NSCLC cell lines (Figure 5B). CXCL8 expression was
significantly induced in two of the three cell lines (HBEC4/
SKMES-1 – p,0.05, Figure 5B). The two receptors CXCR1 and
CXCR2 were significantly induced by DAC in HBEC4 (p,0.01)
(Figure 5A, B). DAC demonstrated the ability to reactivate CXCR1
but not CXCR2 expression in SKMES-1 (p,0.01) (Figure 5A, B).
DAC could induce CXCR2 but not CXCR1 in A549 (p,0.05)
(Figure 5A, B). While this data would suggest that DNA CpG
methylation is involved with the regulation of expression of the
CXC receptors and CXCL8, a search of the UCSC genome
library (http://genome.ucsc.edu/) revealed a sparse number of
CpG residues at the promoter regions of these three genes.
Therefore, we believe a change in the expression levels of this
family maybe due to a secondary effect caused by DAC treatment,
such as the up-regulation of specific transcription factors.
Cellular proliferation of SKMES-1 is decreased in the
presence of recombinant CXCL8, while increased in A549
When treated with various concentrations of recombinant
CXCL8 (0.1–100 ng/mL) for a period of 24–72 h, there was a
trend for a decrease in proliferation in the HBEC cell line relative
to untreated control (data not shown). CXCL8 treatment (100 ng/
mL and 10 ng/mL) caused an increase in proliferation in the
A549 cell line (p,0.01–100 ng/mL, p,0.05–10 ng/mL) at 72 h
post treatment only (Figure 6A). However, there was a significant
decrease in proliferation at 24 h post treatment in SKMES-1
(Figure 6B) at all concentrations tested (p,0.01, 100 ng/mL and
10 ng/mL; p,0.05 1 ng/mL and 10 ng/mL) but not at any other
time point (data not shown). To determine if the proliferative effect
in both of these cell lines was specifically due to CXCL8
treatment, a CXCR2 neutralising approach was undertaken. Cell
lines were treated with SB 225002 at a previously published IC50
value of 22 nM [33] for one hour prior to the addition of CXCL8
at 100 ng/mL for 72 h (A549) and 24 h (SKMES-1) (Figure 6C).
Blockade of the CXCR2 receptor negated the proliferative effect
in both A549 and SKMES-1 cell lines compared to CXCL8
treatment alone.
Discussion
The CXC (ELR
+) chemokine family, a potent pro-angiogenic
family, was found to be regulated epigenetically in both NSCLC
and normal bronchial epithelial cell lines at the level of both
histone post-translational modifications.
In a panel of normal/tumour matched samples, the chemokines
and receptors displayed no altered expression pattern between
changes in expression of the various CXC (ELR
+) chemokines and their receptors in a panel of tumour/normal matched patient NSCLC samples.
C) Overall densitometry analyses of tumour/normal matched patient NSCLC samples. Data is graphed as mean 6 standard error of mean (n=37).
(N – Normal, T – Tumour).
doi:10.1371/journal.pone.0014593.g001
Figure 2. Expression of CXCL1–3, CXCL8 and CXCR1/2 in a panel
of normal and NSCLC cancer cell lines. The panel included A549
(adenocarcinoma), SKMES-1 (squamous cell carcinoma), H460, H647 and
H1299 (large cell carcinoma), BEAS-2B (SV40 transformed normal
bronchoepithelial) and HBEC cell lines (normal bronchial epithelial cell
lines immortalised in the absence of viral oncoproteins). Beta actin is
included to validate loading efficiency. (M – DNA size marker, -ve –
Negative RT-PCR control).
doi:10.1371/journal.pone.0014593.g002
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exception of CXCL3 (average value elevated in squamous cell
carcinoma and reduced in adenocarcinoma). Higher levels of
CXCL8 have been detected by IHC in lung cancer tissue samples
when compared with normal [34], and in our samples levels of
CXCL8 mRNA were elevated in 37.8% (14/37) samples. Although
the overall average densitometry values (adenocarcinoma n=14
and squamous cell carcinoma n=23) indicate a reduction of
Figure 3. Cell line response to histone deacetylase inhibition. A) The effect of TSA treatment (250 ng/mL for 16 h) on the expression of
CXCL1–3, CXCL8 and CXCR1/2. B) Densitometry analysis of expression in treated versus untreated samples when normalised to beta actin. Data is
graphed as mean 6 standard error of mean (n=3). C) Treatment with TSA also effects the production of CXCL2 and CXCL8 at protein level in SKMES-1
cells. Chemokines were quantified in conditioned media removed from culture after exposure to TSA (250 ng/mL for 16 h). Data is graphed as mean
6 standard error of mean (n=3). (UT – untreated, TSA – Trichostatin A).
doi:10.1371/journal.pone.0014593.g003
Figure 4. Histone acetylation occurs directly at the promoter regions of CXCL8 and CXCR1/2. The ChIP assay demonstrates that TSA
treatment results in an increase in the acetylation of histone H3 and H4. A549 cells were cultured in the presence or absence of TSA (250 ng/mL) for a
period of 16 h. Subsequently, a ChIP assay was performed using the following antibodies; pan acetylated histone H3 (Ac H3) and H4 (Ac H4), histone
H3 acetylated at lysine 9 and 14 (H3K9/K14Ac), histone H3 acetylated at lysine 9 (H3K9Ac), histone H3 acetylated at lysine 9 and phosphorylated at
serine 10 (H3K9pS10), Histone H3 dimetylation marker at lysine 9 (H3K9Me2), dimetylation marker at lysine 4 (H3K4Me2) and methylation marker at
lysine 4 (H3K4Me). The chromatin status at the promoter region of (A) CXCL8, (B) CXCR1 and (C) CXCR2 is shown. Input DNA serves as a positive
control recommended by the manufacturer (Diagenode). A no antibody control was included to test for non specific carriage of DNA with histones.
(M – DNA size ladder).
doi:10.1371/journal.pone.0014593.g004
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for every individual sample (Figure 1 A). Due to the heterogenicity
of the samples, it is difficult to make a definitive conclusion based
on these results. It must be noted however, that expression of
many of the chemokines were most often found to be
downregulated in the NSCLC tumours as follows CXCL1
(64.9%, p,0.01), CXCL2 (81.1%, p,0.01), CXCL3 (59.5%)
(Figure 1B). In addition, levels of CXCR1 were also found to be
significantly reduced in NSCLC tumours (35.2%, p,0.05).
In a panel of NSCLC cell lines treated with HDACi there was a
decrease in CXCL1–3 with a concomitant increase in CXCL8 and
the receptors CXCR1 and 2 (Figure 3B). TSA has previously been
shown to up-regulate CXCL8 in lung [35] and breast cancer cell
lines [36]. The reactivation of these receptors in the lung cancer
cell lines would indicate that they are under epigenetic regulation
at the level of histone modification. The general dogma associated
with HDACi is that they function to induce gene expression.
However in this study, TSA caused both an up- and down-
regulation of the chemokines, an effect seen by others in other
studies. For example, HDACi have been shown to down-regulate
Wilms tumour gene 1 (Wt1) [37] and EGFR [38]. Limited
availability of specific transcription factors may result in only a
certain number of up-regulated genes. As such the activation of
CXCL8 may lead to the down regulation to CXCL1–3, either via a
Figure 5. Cell line response to a DNA methyltransferase inhibitor. A) The effect of 5-aza-29deoxycytidine (DAC) treatment on the expression
of CXCL1–3, CXCL8 and CXCR1/2. Cells were cultured in 1 mM DAC for 48 h with media and drug replaced every 24 h. Expression changes were
measured using RT-PCR with Beta-Actin used as the internal control for quantification purposes. B) Densitometry analysis of expression in treated
versus untreated samples when normalised to beta actin. Data is graphed as mean 6 standard error of mean. (n=3). (DAC – 5-aza-29deoxycitidine).
doi:10.1371/journal.pone.0014593.g005
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away from the promoter regions of these genes. ChIP results
indicate that TSA acts by directly remodelling the promoter region
of the CXCL8 and CXCR1/2 genes (Figure 4). Our ChIP results
show that histones H3 and H4 become hyperacetylated at these
gene promoters, involving lysines 9 and 14 of histone H3, and
lysines 5, 8, 12 and 16 of histone H4. We observe a strong increase
in the levels of histone H3 lysine 4 dimethylation (H3K4me2)
following activation of transcription via HDACi, and also observe
a loss of histone lysine 4 monomethylation (H3K4me), following
activation of CXCL8/CXCR1/CXCR2. In agreement with the
current literature, we observe the presence of a repressive mark
H3K9Me2 at the PGIS promoter prior to activation via HDACi,
and levels of this histone modification decrease following
activation [39,40]. These results verify that HDACi causes causes
chromatin remodelling via histone post-translational modifications
around the promoter region of the genes examined indicating that
it is active element in the regulation of these chemokines and their
receptors.
DNA CpG methylation is also a major component in epigenetic
regulation of gene expression. Hypermethylated DNA is often
found in the promoter regions of tumour suppressor genes in
cancers, particularly in lung cancer [30]. Treatments with the
DNMTi DAC reactivated the expression of CXCR1 in the A549
(Figure 5B) cell line and CXCR2 in SKMES-1 (Figure 5B).
However, searches of both promoter databases and the genome
failed to find any significant CpG islands in the promoter regions
of these genes, indicating therefore that the reactivation of these
receptors is an indirect effect of DNMTi treatment, perhaps by the
reactivation of a transcription factor necessary for these genes to
be transcribed.
The CXC (ELR
+) chemokines are important in neo-vascular-
isation and metastasis. This study has demonstrated that CXCL8
can be up-regulated by epigenetic targeting using HDACi or
DNMTi. Current literature indicates that CXCL8 is a chemokine
involved in carcinogenic processes by stimulating cellular prolif-
eration in some NSCLC cell lines [41,42,43], but results are
conflicting [44]. In this study, treatment with recombinant
CXCL8 failed to induce proliferation in a normal cell line (data
not shown) and significantly decreased proliferation in the
SKMES-1 cell line at 24 h post treatment (Figure 6B). Conversely
proliferation was increased in A549 after 72 h exposure to
CXCL8 (Figure 6A). Treatment with a selective non peptide
CXCR2 inhibitor (SB 225002) prevented the proliferative
Figure 6. The growth effect of CXCL8 varies between NSCLC sub-type but is negated by neutralizing the CXCR2 receptor. A) Cell
proliferation was examined by BrdU assay following 24–72 h treatment with CXCL8 in A549 (72 h post treatment) and SKMES-1 (24 h post treatment)
cell lines. Only time points with significant data is shown. Data is represented as a percentage of the untreated control (UT), which was set to 100%
and is expressed as mean 6 SEM. (n=3) (e p,0.01 – CXCL8 treatment vs. UT, y p,0.05 – CXCL8 treatment vs. UT) B) Cell lines were treated with a
selective CXCR2 antagonist (0.022mM) for 1 h prior to the addition of CXCL8 and cultured for a period of 24 (SKMES-1) or 72 h (A549). Data is
represented as a percentage of the untreated control (UT), which was set to 100% and is expressed as mean 6 SEM. (n=3).
doi:10.1371/journal.pone.0014593.g006
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ing that such responses were due to CXCL8 signalling through
functional CXCR2 receptors.
Very low basal receptor expression was observed in the NSCLC
cancer cells, whereas expression was strong in the normal cell lines
(Figure 2), which may suggest that the receptors are important in
normal physiological processes. Although the expression of CXC
receptors correlates with increased tumour angiogenesis and growth,
in some circumstances the loss of receptor expression may contribute
to carcinogenesis [8]. A recent study published by Ohri et al,f o u n d
that a high expression of CXCR2 in tumour islets is associated with
increased survival in NSCLC [45]. In human fibroblasts, CXCR2
has been shown as an important mediator of senescence, activating a
DNA damage check-point [46]. Therefore, the loss of CXC receptor
expression may allow for neoplastic cells to escape senescence,
resulting in cancer promotion. The seemingly dual function of
CXCR2 may explain the conflicting results concerning CXCL8 as a
growth factor. Other findings suggest that CXCL1 or CXCL8
signalling may reduce tumour growth by promoting senescence
through CXCR2 [47]. Therefore, epigenetic targeting of this family
may be of potential therapeutic benefit, as our results indicate that
CXCR2 and CXCL8 can be induced by epigenetic means.
Chemokines are important in cancer as they possess the ability
to promote organ specific metastases making them an attractive
therapeutic target, particularly as 90% of cancer related deaths are
due to tumour metastases. Our results clearly demonstrate that the
expression of the CXC (ELR
+) family is commonly disrupted in
NSCLC. Furthermore, we have established that these chemokines
and their cognate receptors are regulated epigenetically, and may
represent good targets for epigenetic therapy in the treatment of
NSCLC. Further experimental work will be necessary to delineate
these possibilities and to determine if the aberrant epigenetic
regulation of these genes plays a role in NSCLC pathogenesis.
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